PRQR News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PR

Mkt Cap

$184.6M

Volume

1.02M

Next Earnings

November 5th

Loading chart

PR

PRQRProQR Therapeutics N.V. Ordinary Shares

PRQR

Pay with—

Available Balance0.00

PR

Mkt Cap

$204.6M

Volume

1.02M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of DirectorsProQR Therapeutics announced the nomination of Dr. Lykke Hinsch Gylvin, Chief Medical Officer at Boehringer Ingelheim, to its Board of Directors. Dr. Gylvin brings over 20 years of pharmaceutical leadership experience from roles at Boehringer Ingelheim, Novartis, AstraZeneca, Roche, Novo Nordisk, and Lundbeck. The nomination will be submitted for shareholder approval at the upcoming Annual General Meeting.GlobeNewswire Inc. · Apr 30, 2026

ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst EventProQR Therapeutics announced pipeline expansion with multiple clinical programs advancing toward the clinic. The company's lead program AX-0810 is on track to report target engagement data in H1 2026, with biliary atresia selected as the initial Phase 2 indication. Additional programs AX-0811, AX-0422, and AX-2911 are progressing with anticipated CTA filings and clinical data readouts expected through 2027. ProQR expects to deliver multiple clinical data readouts within its current cash runway extending into mid-2027.GlobeNewswire Inc. · Apr 8, 2026

ProQR Announces Year End 2025 Operating and Financial ResultsProQR Therapeutics reported €92.4 million in cash at year-end 2025 and advanced its lead program AX-0810 into Phase 1 testing for cholestatic diseases, with target engagement data expected in H1 2026. The company selected development candidates AX-2402 for Rett syndrome and AX-2911 for MASH, achieved $4.5 million in Eli Lilly collaboration milestones, and projects cash runway into mid-2027. R&D costs increased to €44.7 million and net loss widened to €42.2 million for 2025.GlobeNewswire Inc. · Mar 12, 2026

ProQR to Participate in 8th Annual Evercore Healthcare ConferenceProQR Therapeutics will participate in the 8th Annual Evercore Healthcare Conference, presenting its Axiomer™ RNA editing technology platform that enables targeted single nucleotide changes in RNA to potentially develop new disease treatments.GlobeNewswire Inc. · Dec 1, 2025

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025ProQR Therapeutics received Clinical Trial Application (CTA) authorization from the Central Committee on Research Involving Human Subjects for a Phase 1 study of AX-0810, an investigational RNA editing oligonucleotide targeting NTCP for cholestatic diseases. The company will host a virtual investor event on November 3, 2025 to discuss the clinical trial.GlobeNewswire Inc. · Oct 20, 2025

ProQR Announces First Quarter 2025 Operating and Financial ResultsProQR Therapeutics reported its Q1 2025 financial results, highlighting progress in its Axiomer RNA editing pipeline, including the advancement of its lead program AX-0810 targeting NTCP for cholestatic diseases towards a CTA filing in Q2 2025. The company also strengthened its leadership team with new CFO and CMO appointments.GlobeNewswire Inc. · May 8, 2025

ProQR Announces Year End 2024 Operating and Financial ResultsProQR Therapeutics is advancing its Axiomer™ ADAR-mediated RNA editing pipeline, with plans to file a CTA for its lead program AX-0810 targeting NTCP for Cholestatic diseases in Q2 2025. The company expects up to four clinical data readouts in 2025 and 2026, and has a strong financial position with €149.4 million in cash and cash equivalents as of the end of 2024.GlobeNewswire Inc. · Mar 13, 2025

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR ScientistProQR Therapeutics, a company focused on RNA therapies, has appointed Dr. Peter Beal, a leading expert in ADAR and RNA biology, as its Chief ADAR Scientist. Dr. Beal will oversee the optimization and development of ProQR's Axiomer RNA editing platform.GlobeNewswire Inc. · Dec 10, 2024

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private PlacementProQR Therapeutics, a company focused on RNA therapies, has announced the closing of a $63.0 million public offering and a $12.3 million private placement with Eli Lilly and Company.GlobeNewswire Inc. · Oct 25, 2024

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private PlacementProQR Therapeutics announced the pricing of a $63.0 million public offering of 18 million ordinary shares at $3.50 per share. The company also entered into a concurrent private placement with existing shareholder Eli Lilly and Company to maintain its pro rata ownership.GlobeNewswire Inc. · Oct 23, 2024

to start trading

PR

PRQRProQR Therapeutics N.V. Ordinary Shares

PRQR

Pay with—

Available Balance0.00

Your PositionYou don't own any PRQR yet.

Related Tickers

Earnings